A Phase 4 interventional study of Propofol and Dexmedetomidine in Traumatic Brain Injuries, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Assiut University · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing dexmedetomidine in Brain Injuries, Traumatic — 5 open to participants now, 5 under way, 2 of them phase 3. Dexmedetomidine · Brain Injuries, Traumatic.
Among the 10 studies testing dexmedetomidine in Brain Injuries, Traumatic, this one is the 4th largest by planned enrollment, is one of 2 that started in 2026, is one of 3 in phase 4, and was the 10th registered.
1,724 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →5 of the 10 studies testing dexmedetomidine in Brain Injuries, Traumatic are open now, in 1 country. Recruiting first, the newest first:
Aswan University · Sites in Egypt
Ages 18+
Benha University
Ages 18+
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Ages 18+
Assiut University
Ages 18–45
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 285 Brain Injuries, Traumatic studies recruiting now, 124 (44%) set no upper age limit and 119 (42%) stop at 75 or younger; 40 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2 · Phase 4 3
First in 2010; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 52 across 1,090 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 76 across the 10 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 8 most frequent:
Assiut University is the lead sponsor of 5,092 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
15 studies in Brain Injuries, Traumatic by Assiut University: 10 open now, 10 under way, 1 of them phase 3. Of 3 finished, 0 (0%) have results posted.
Among the 15 studies in Brain Injuries, Traumatic by Assiut University, this one is one of 8 that started in 2026, is one of 2 in phase 4, and was the 14th registered.
Assiut University’s Brain Injuries, Traumatic studies by the year they started, since 2021.
1 of the studies testing dexmedetomidine in Brain Injuries, Traumatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07807579Assiut UniversityImpact of Dexmedetomidine Versus Propofol on Intracranial Pressure in Adult Traumatic Brain Injury Patients: Randomized Controlled Double-Blind Trial | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing dexmedetomidine in Brain Injuries, Traumatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Assiut University’s 15 in Brain Injuries, Traumatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate whether dexmedetomidine or propofol is more effective in controlling intracranial pressure (ICP) (assessed via optic nerve sheath diameter "ONSD" as a primary outcome) and which is more effective in suppressing lipid peroxidation (measured via malondialdehyde "MDA" as a secondary outcome). This double-blind randomized controlled trial aims to bridge this research gap by evaluating the biochemical neuroprotective efficacy alongside the clinical outcomes of both agents in TBI patients.
Traumatic brain injury (TBI) remains a leading cause of mortality and permanent disability worldwide, posing a major challenge in neurocritical care. The primary injury occurs at the moment of impact, resulting in immediate mechanical tissue disruption. However, the subsequent secondary brain injury develops over hours to days, driven by complex cascades of neuroinflammation, excitotoxicity, mitochondrial dysfunction, and severe oxidative stress (Werner and Engelhard, 2007).
Oxidative stress is characterized by an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defense mechanisms. The brain is particularly vulnerable to oxidative damage due to its high oxygen consumption, high lipid content (especially polyunsaturated fatty acids), and relatively low levels of antioxidant enzymes (Hall et al., 2010). During secondary injury, massive ROS production leads to lipid peroxidation, a process that degrades cell membranes and disrupts cellular integrity. Malondialdehyde (MDA) is a well-established, highly stable end-product of lipid peroxidation. Elevated systemic and cerebrospinal fluid levels of MDA serve as a reliable and sensitive biomarker for quantifying the severity of oxidative stress and predicting neurological outcomes in TBI patients (Lorente et al., 2015).
Sedation is a cornerstone in the management of mechanically ventilated TBI patients in the Intensive Care Unit (ICU). It is essential to decrease metabolic demands, facilitate mechanical ventilation, prevent spikes in intracranial pressure (ICP), and control agitation (Roberts et al., 2011).
Dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, has emerged as a promising alternative in neurointensive care. It provides "conscious sedation" without causing significant respiratory depression, allowing for easier neurological evaluation. Beyond its sedative properties, evolving preclinical and clinical evidence suggests that dexmedetomidine exerts potent neuroprotective effects (Arain and Ebert, 2002). These effects are hypothesized to be mediated through the reduction of central sympathetic outflow, attenuation of neuroinflammation, and direct modulation of oxidative stress pathways, leading to a reduction in lipid peroxidation biomarkers like MDA (Wang et al., 2019).
Propofol is a lipid-soluble anesthetic, used intravenously in the clinics for sedation in the ICU and for general anesthesia. The antioxidant properties of propofol have been attributed to the similarity of its chemical structure to known antioxidants such as butylhydroxytoluene and α-tocopherol. It has been reported that the antioxidant properties of propofol are not only inhibiting lipid peroxidation, but also scavenging the ROS that have been formed (Demiryürek et al., 1998).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 patients will be received Propfol at a continuous infusion dose of 5-50 mcg/kg/min.
Drug: Propofol
40 patients will be received Dexmedetomidine at a continuous infusion dose of 0.2-0.7 mcg/kg/hour without a loading dose to avoid hemodynamic instability.
Drug: Dexmedetomidine
evaluate intracranial pressure and serum Malondialdehyde (MDA) levels
evaluate intracranial pressure and serum Malondialdehyde (MDA) levels
Non-invasive intracranial pressure monitoring by optic nerve sheath diameter measurement.
Time frame: every 6 hours for 48 hours
Serum Malondialdehyde (MDA) levels.
Time frame: At 0 hours and after 48 hours
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Nov 2027, 13 months later.
Of 25 phase 4 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 148. This study's planned 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Propofol · Dexmedetomidine